Endothelial Dysfunction, a Marker of Atherosclerosis, Is Independent of Metabolic Syndrome in NAFLD Patients

Background. The study was designed to assess cardiovascular risk factors flow-mediated dilatation % (FMD%) and carotid intima-media thickness (CIMT) in NAFLD. Methods. 126 NAFLD subjects and 31 chronic hepatitis B (CHB) controls were studied. Measuring carotid intima-media thickness (CIMT) and the flow-mediated dilatation % (FMD%) by brachial artery Doppler ultrasound were used to assess atherosclerosis. The risk of cardiac events at 10 years (ROCE 10) was estimated by the Prospective Cardiovascular Munster Study (PROCAM) score. Results. 58 of 126 NAFLD have coexistent metabolic syndrome. Mean CIMT was 0:73 ± 0:041 mm among NAFLD with MS, 0:66 ± 0:016 mm among NAFLD without MS, and 0:66 ± 0:037 in controls CHB patients. FMD% in NAFLD with MS was 10:43 ± 3:134%, but was 8:56 ± 3:581% in NAFLD without MS and 17:78 ± 6:051% in controls. PROCAM score of NAFLD with MS was 46:95 ± 6:509 while in NAFLD without MS was 38:2±3:738. Controls had a PROCAM score of 38:13 ± 5:755. ROCE 10 in NAFLD with MS was 13:64 ± 8:568 while NAFLD without MS was 5:55 ± 1:949. Controls have a ROCE 10 of 5:95 ± 3:973. Post hoc analysis showed CIMT was dependent upon MS while FMD% was different between all subgroups hence independent of metabolic syndrome. Conclusion. The markers of endothelial dysfunction are significantly higher in patients with NAFLD than controls.